… Next, we used individual RTK inhibitors to demonstrate that SHP2-dependent pathway
reactivation is due to RTK activity and to identify which RTKs were responsible in KRAS-mutant …

… SHP2 inhibition acts upstream of RAS to abrogate MEKi–evoked ERK MAPK pathway
reactivation. A and B, Immunoblots of whole-cell lysates or GST-RBD–precipitated (RAS-GTP, …

… by reactivation of RAS-MEK-ERK and AKT pathways. Combined use of SHP2 inhibitor (10)
with sorafenib can block the reactivation of MEK/ERK and AKT signaling pathways, thus …

… pathway inhibition by SHP2 inhibitors may promote the open conformation of SHP2 and
lead to resistance to SHP2 inhibitors. … this RAS reactivation following initial SHP2 inhibition is …

… of MEK induces negative feedback to increase the RTK activity that leads to the reactivation
of RAS/Raf/ERK pathway or increases the activities of other cascades, such as PI3K/AKT …

… mTOR inhibition in HCC which, through SHP2, leads to reactivation of the mTOR pathway. …
We show here that a combination of mTOR and SHP2 inhibitors is highly synergistic in …

… data as to whether PTPN11 mutational status determines SHP2 inhibitor sensitivity in non-neuroblastoma
cells, we assessed the efficacy of SHP2 inhibitors in isogenic SH-EP and Kelly …

… of SHP2 in RAS-driven cancers and the therapeutic potential of allosteric SHP2 inhibitors as
… Reactivation of RAS pathway signaling may underlie the lack of therapeutic efficacy, as with …

… of how SHP-2 shapes these pathways and highlight open questions that—with the advent
of … or pharmacological inhibition of SHP-2 by the inhibitor GS493 prevented re-activation of …

… reactivation of KRAS G12C . Although normal KRAS/other RAS isoforms might also be
reactivated… be the main effector of ERK pathway reactivation. Consistent with this conclusion, ARS …